We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.9B
1-Year Est. Return 169.69%
This Fund
S&P 500
This Quarter Est. Return
+26.15%
1 Year Est. Return
+169.69%
3 Year Est. Return
+507.65%
5 Year Est. Return
+746.04%
10 Year Est. Return
–
AUM
$2.9B
AUM Growth
+$433M
Cap. Flow
-$46.5M
Cap. Flow %
-1.6%
Top 10 Hldgs %
48.91%
Holding
114
New
21
Increased
25
Reduced
41
Closed
17

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$81.1M
2
INSP icon
Inspire Medical Systems
INSP
+$64.3M
3
RIGL icon
Rigel Pharmaceuticals
RIGL
+$56.6M
4
CELC icon
Celcuity
CELC
+$48.5M
5
PBLS
Parabilis Medicines Inc
PBLS
+$40.5M

Top Sells

Rank Stock Value
1
TWST icon
Twist Bioscience
TWST
+$73M
2
KRYS icon
Krystal Biotech
KRYS
+$63.9M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$48.4M
4
TGTX icon
TG Therapeutics
TGTX
+$45.1M
5
VCEL icon
Vericel Corp
VCEL
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZNTL icon
76
Zentalis Pharmaceuticals
ZNTL
$378M
$4.61M 0.16%
+950,000
New +$3.79M
KPTI icon
77
Karyopharm Therapeutics
KPTI
$40.6M
$4.3M 0.15%
440,000
– –
CNTX icon
78
Context Therapeutics
CNTX
$33.2M
$3.91M 0.13%
7,063,141
+100,000
+1% +$203K
LUNG icon
79
Pulmonx
LUNG
$94.9M
$3.62M 0.12%
2,788,323
– –
SABS icon
80
SAB Biotherapeutics
SABS
$338M
$3.51M 0.12%
900,000
-150,000
-14% -$558K
TECX
81
Tectonic Therapeutic
TECX
$601M
$3.5M 0.12%
101,684
-20,000
-16% -$588K
AXGN icon
82
Axogen
AXGN
$2.6B
$2.63M 0.09%
57,036
-622,134
-92% -$25.1M
MSLE
83
Satellos Bioscience
MSLE
$190M
$2.44M 0.08%
314,359
-100,000
-24% -$687K
AVBP icon
84
ArriVent BioPharma
AVBP
$1.53B
$1.74M 0.06%
+50,000
New +$1.48M
CORT icon
85
Corcept Therapeutics
CORT
$12.1B
$1.71M 0.06%
19,653
-265,878
-93% -$16.1M
SLDB icon
86
Solid Biosciences
SLDB
$1.1B
$1.5M 0.05%
+150,000
New +$1.14M
VCYT icon
87
Veracyte
VCYT
$3.42B
$1.47M 0.05%
25,000
-294,912
-92% -$12.4M
CGEM icon
88
Cullinan Oncology
CGEM
$1.42B
$911K 0.03%
50,000
-360,200
-88% -$5.35M
NSPR icon
89
InspireMD
NSPR
$40M
$732K 0.03%
1,045,708
– –
WGS icon
90
GeneDx Holdings
WGS
$2.56B
$687K 0.02%
+10,000
New +$568K
IOVA icon
91
Iovance Biotherapeutics
IOVA
$3.98B
$624K 0.02%
150,000
-850,000
-85% -$3.23M
LRMR icon
92
Larimar Therapeutics
LRMR
$398M
$574K 0.02%
188,102
-878,858
-82% -$3.49M
CGON icon
93
CG Oncology
CGON
$6.62B
$355K 0.01%
5,000
-15,000
-75% -$981K
QNRX
94
Quoin Pharmaceuticals
QNRX
$14.6M
$352K 0.01%
72,730
– –
EQ icon
95
Equillium
EQ
$140M
$288K 0.01%
+90,000
New +$216K
NTRA icon
96
Natera
NTRA
$47.3B
$271K 0.01%
1,000
-118,000
-99% -$25.2M
NEO icon
97
NeoGenomics
NEO
$2.23B
$146K 0.01%
10,000
-165,000
-94% -$1.59M
ANAB icon
98
AnaptysBio
ANAB
$1.68B
– –
-6,000
Closed -$333K
ARWR icon
99
Arrowhead Research
ARWR
$12.2B
– –
-28,479
Closed -$1.79M
COGT icon
100
Cogent Biosciences
COGT
$6.03B
– –
-10,000
Closed -$385K
1 2 3
4
5

Similar funds

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
7WCP
71 West Capital Partners Boston, Massachusetts $2.89B AUM
ACM
Aquatic Capital Management Chicago, Illinois $2.91B AUM 27.09% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.91B AUM 24.25% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.89B AUM 29.25% 1-Year Est. Return
WPW
Waldron Private Wealth Bridgeville, Pennsylvania $2.89B AUM 23.18% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Soleus Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Soleus Capital Management held 114 positions worth $2.9B, up 18% from $2.47B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Soleus Capital Management's Q2 2026 filing shows 21 new, 25 increased, 41 reduced and 17 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M. The largest sale was Twist Bioscience, an estimated $73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Soleus Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M.
  • Soleus Capital Management added most to Insulet in Q2 2026, an estimated $81.1M increase.
  • Soleus Capital Management's biggest Q2 2026 reduction was Twist Bioscience, cutting an estimated $73M.
  • Soleus Capital Management fully exited Vaxcyte in Q2 2026, selling an estimated $22.4M.
  • Soleus Capital Management's ten largest holdings make up 49% of its $2.9B portfolio in Q2 2026.
  • Soleus Capital Management opened 21 new positions and closed 17 in Q2 2026.
  • Soleus Capital Management's portfolio value rose 18% quarter-over-quarter to $2.9B.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.